Literature DB >> 9676367

[Adjustable "banding" of the hepatic artery in treatment of shunt-induced heart failure in Osler-Rendu-Weber disease].

J Zieren1, R Büttemeyer, J M Müller.   

Abstract

Hepatic involvement in hereditary hemorrhagic telangiectasia (HHT) is rare. Among local pathologic alterations like fibrosis and cirrhosis, arteriovenous shunts lead to hypercirculatory heart failure and require efficient therapy. Present therapeutic strategies consist of percutaneous selective embolization or complete ligation of the hepatic artery. We describe a 53-year-old woman with HHT in whom percutaneous selective embolization of the left hepatic artery failed because of unfavorable anatomy. Instead of ligation a new method of adjustable banding of the hepatic artery was tested. After small-incision laparotomy an expander prosthesis was put on the proper hepatic artery. By filling the prosthesis via the implanted port system the hepatic perfusion could be reduced under control. This method led to effective reduction of the liver perfusion and heart time volume and to successful treatment of heart failure. The method described is an alternative treatment to ligation of the hepatic artery in cases in which percutaneous embolization failed or is not possible.

Entities:  

Mesh:

Year:  1998        PMID: 9676367     DOI: 10.1007/s001040050468

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  2 in total

1.  Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations.

Authors:  Ajay Chavan; Martin Caselitz; Karl-Friedrich Gratz; Joachim Lotz; Timm Kirchhoff; Plinio Piso; Siegfried Wagner; Michael Manns; Michael Galanski
Journal:  Eur Radiol       Date:  2004-08-17       Impact factor: 5.315

2.  Treatment of high output cardiac failure by flow-adapted hepatic artery banding (FHAB) in patients with hereditary hemorrhagic telangiectasia.

Authors:  A Koscielny; W A Willinek; A Hirner; M Wolff
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.